Array BioPharma Inc. (ARRY) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $10.58, down from yesterday’s close by -1.86%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.
No amount of research is complete without a bird’s eye view of the financial data. Array BioPharma Inc. (ARRY) currently trades with a market capitalization of $2.02 Billion. That value represents a market adjusting for revenues that have been falling by -24.25 % on a quarterly year/year basis as of the company’s last quarterly report.
The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For ARRY, the company currently has $295.41 Million of cash on the books, which is offset by $12.4 Million current liabilities. You can get a sense of how sustainable that is by a levered free cash flow of $-45.3 Million over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of $-0.23 on a per share basis this quarter. Perhaps, that suggests something about why 89.05% of the outstanding share supply is held by institutional investors.
Sometimes, we can understand most about a stock by simply looking at how it has been trading. Looking at the stock’s movement on the chart, Array BioPharma Inc. recorded a 52-week high of $13.40. It is now trading 2.82% off that level. The stock is trading $11.37 its 50-day moving average by 0.79%. The stock carved out a 52-week low down at $6.73.
In recent action, Array BioPharma Inc. (ARRY) has made a move of -7.68% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 17.32, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 11.83% with $190.55 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of ARRY.